Brought to you by 
Baxter, Sangamo develop vascular disease therapeutics
04 Feb 2002
Executive Summary
Sangamo BioSciences (transcription factors) has licensed Baxter International's cardiovascular group (therapeutics for cardiovascular and other diseases; soon to be spun off as an independent company called Edwards Lifesciences) exclusive worldwide rights to develop and commercialize its zinc finger DNA binding proteins (ZFPs) for use in cardiovascular and other vascular diseases.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter, Sangamo develop vascular disease therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice